Hearing Requested to Avoid Suspension

Sinovac Biotech Ltd. Received a delist determination letter from Nasdaq on May 22, 2026, due to not filing its 2025 annual report on time, breaching Nasdaq’s Periodic Filing Rule. This lapse could lead to the suspension and delisting of its securities if not addressed swiftly.

By January 21, 2026, a Nasdaq panel required Sinovac to demonstrate compliance with filing rules by May 11, 2026. Sinovac successfully submitted its 2024 annual report and an interim financial statement for the second quarter of 2025 before the deadline. However, the delay in the 2025 annual report submission triggered the current crisis.

In response, Sinovac has requested a hearing to contest the delisting warning. This request automatically stays any suspension of its securities for 22 days from the determination letter’s date, providing Sinovac time to prepare its case and potentially avoid delisting.

The Nasdaq Panel Monitor will oversee Sinovac for a year. If further non-compliance is noted, Nasdaq will issue another delist determination, necessitating a new hearing to prevent delisting. Sinovac’s ability to meet compliance standards is crucial for maintaining its Nasdaq listing.

Founded in Beijing, Sinovac is a leading player in the vaccine industry, offering WHO-prequalified vaccines. The company focuses on expanding its global footprint through strategic partnerships and technological advancements. Sinovac aims to resolve the current filing delay and fully adhere to Nasdaq’s regulatory standards. The outcome of the hearing will significantly impact Sinovac’s future on the Nasdaq exchange.

Sinovac operates under the mission to supply vaccines that combat human diseases, emphasising research, development, manufacturing, and commercialization of vaccines. The current compliance issues underscore the challenges faced by international businesses in adhering to stringent regulatory standards.

Last updated: 29 June 2026, 11:58 am